HRCM
CYTK icon

Hood River Capital Management’s Cytokinetics CYTK Stock Holding History

Hood River Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40M Buy
+469,273
New +$33.7M 0.29% 99
2026
Q1 		– Sell
-137,597
Closed -$8.74M – 175
2025
Q4 		$8.74M Buy
+137,597
New +$8.56M 0.1% 129
2025
Q2 		– Sell
-1,256,580
Closed -$50.5M – 157
2025
Q1 		$50.5M Buy
1,256,580
+267,332
+27% +$12.3M 0.86% 50
2024
Q4 		$46.5M Sell
989,248
-1,548
-0.2% -$80.4K 0.69% 59
2024
Q3 		$52.3M Buy
990,796
+253,159
+34% +$14.1M 0.84% 47
2024
Q2 		$40M Buy
737,637
+40,990
+6% +$2.47M 0.83% 48
2024
Q1 		$48.8M Buy
696,647
+135,666
+24% +$10.5M 1.09% 30
2023
Q4 		$46.8M Buy
560,981
+58,455
+12% +$2.12M 1.29% 29
2023
Q3 		$14.8M Sell
502,526
-1
-0% -$33 0.48% 73
2023
Q2 		$16.4M Buy
502,527
+16,255
+3% +$601K 0.49% 71
2023
Q1 		$17.1M Buy
486,272
+10,799
+2% +$441K 0.55% 62
2022
Q4 		$21.8M Sell
475,473
-394,479
-45% -$17M 0.79% 51
2022
Q3 		$42.1M Buy
869,952
+18,047
+2% +$869K 1.61% 19
2022
Q2 		$33.5M Buy
851,905
+46,331
+6% +$1.87M 1.33% 25
2022
Q1 		$29.7M Buy
805,574
+185,910
+30% +$6.61M 0.99% 38
2021
Q4 		$28.2M Sell
619,664
-3,992
-0.6% -$154K 0.85% 45
2021
Q3 		$22.3M Buy
+623,656
New +$18.4M 0.69% 53

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hood River Capital Management's CYTK Position: Q2 2026 in Review

Hood River Capital Management opened a new position in Cytokinetics (CYTK) in Q2 2026: 469,273 shares worth $40M. The stake represents 0.29% of the portfolio and ranks #99 among its holdings. This is a return to the name: Hood River Capital Management previously reported a position in CYTK as recently as Q4 2025.

Hood River Capital Management first reported a position in CYTK in Q3 2021 and has held it in 17 quarters since. The position peaked at $52.3M in Q3 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Hood River Capital Management held 469,273 shares of Cytokinetics worth $40M as of Q2 2026.
  • Cytokinetics was a new Hood River Capital Management position in Q2 2026.
  • Cytokinetics made up 0.29% of Hood River Capital Management's portfolio in Q2 2026, its #99 holding.
  • Hood River Capital Management first reported a position in Cytokinetics in Q3 2021 and has held it in 17 quarters since.
  • Hood River Capital Management's Cytokinetics position peaked at $52.3M in Q3 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Hood River Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.